Characterization of osimertinib (AZD9291)-resistant non-small cell lung cancer NCI-H1975/OSIR cell line

Osimertinib (OSI, also known as AZD9291) is the newest FDA-approved epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor for non-small cell lung cancer (NSCLC) patients with EGFR T790M mutation. However, resistance to OSI is likely to progress and the study of potential OSI-resistant me...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Zheng-Hai, Jiang, Xiao-Ming, Guo, Xia, Fong, Chi Man Vivienne, Chen, Xiuping, Lu, Jin-Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5348415/
https://www.ncbi.nlm.nih.gov/pubmed/27835594
http://dx.doi.org/10.18632/oncotarget.13150

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5348415/
https://www.ncbi.nlm.nih.gov/pubmed/27835594
http://dx.doi.org/10.18632/oncotarget.13150

Ejemplares similares